top of page

Search Results

Results found for "Confo Therapeutics"

  • Ever Wondered How Drugs Are Discovered?

    How do molecules make the leap from laboratory concept to therapeutic reality? miss the forest for the trees The critical importance of translation —turning lab data into meaningful therapeutic

  • GPCR Drug Discovery at Discovery on Target: Why This Track Is About More Than Receptors

    diabetes to cancer, fibrosis, and CNS disorders — GPCRs  are at the heart of the world’s most pressing therapeutic Class in Drug Discovery GPCRs regulate countless physiological processes, making them a goldmine for therapeutic But the real  excitement is in what’s next: Biased signaling  for selective therapeutic effects. Orphan GPCRs  with untapped therapeutic potential. you’re in early discovery or clinical development, the strategies here could open doors in your own therapeutic

  • 📰 GPCR Weekly News, January 16 to 22, 2023

    cells and collective calcium transients: an integrated framework combining live cell imaging using confocal Industry News Addex Provides Corporate Update And Financial Guidance Structure Therapeutics Appoints Industry Leaders Eric Dobmeier and Joanne Waldstreicher to its Board of Directors GPCR Therapeutics launches

  • Profiling Immune Cell and Platelet Transcriptomes

    signaling, influencing a wide array of physiological processes and serving as critical targets for therapeutic significant findings that enhance our understanding of GPCRs' roles in immune function and potential therapeutic macrophages suggest that these GPCRs could be targeted to modulate inflammatory responses, offering potential therapeutic the field continues to evolve, the insights gained from this research will be instrumental in shaping therapeutic

  • How GPCR Spatial Signaling Sparked a Scientific Journey

    For innovators building tools, platforms, or therapeutics, these origin moments are where tomorrow’s receptors control localised signaling, how disease hijacks these systems, and how to target them for therapeutic Her work sits at the intersection of fundamental biology and therapeutic strategy. Knowing where  signals occur could unlock new therapeutic strategies, better efficacy, and fewer side

  • Understanding Orthosteric Binding: The Key to Drug Action

    This foundational knowledge guides researchers in the development of new therapeutics. It can inform decisions in drug design, improving therapeutic outcomes and reducing unwanted side effects This understanding can enhance your appreciation for drug development and therapeutic action.

  • Targeting GPCRs in the CNS: Advances in Drug Discovery Strategies

    and the complexity of the central nervous system (CNS) pose a challenge for developing successful therapeutics Emerging GPCR Therapeutic Targets in CNS Drug Discovery GPCRs have been studied for decades, but there Of the traditional GPCRs, CBRs are gaining ground as potential therapeutic targets in several CNS diseases One of the best tools to study therapeutic targets are fluorescent ligands , which are very useful in G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative

  • Inside Out: Mapping GPCRs from Membrane Codes to Market Moves

    Selection  – Master GPCR behavior beyond second messengers   Build sharper strategies for GPCR-targeted therapeutics receptor biology—and how they’re being used to de-orphanize GPCRs, explore autoantibodies, and uncover new therapeutic

  • New Podcast, Sweet Structures & $2.2B GPCR Moves

    mGluR2, and a big headline, Novo Nordisk’s $2.2B deal with Septerna to develop GPCR-targeted obesity therapeutics Biased signalling of Class B G protein-coupled receptor-targeted therapeutics .  

  • Enhancing GPCR Research Outreach | Dr GPCR University early-bird registration ends soon!

    for Drug Discovery DMS: Linking Protein Structure To Function AbbVie Completes Acquisition of Cerevel Therapeutics Nxera Pharma attended the Drug Discovery Ecosystem Summit Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million Tectonic Therapeutic Announces

  • Dr. GPCR and Celtarys Research Join Forces to Expand Access to Innovative GPCR Tools

    Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic

  • 📰 GPCR Weekly News, December 11 to 17, 2023

    This week's highlights: Kudos to our partner, GPCR Therapeutics, for partnering with Bridge Biotherapeutics acids conjugation with [Cp*Rh(H2O)3]2+ by using the meta-dynamics/FMO3 approach Industry News GPCR Therapeutics - Providing the next generation of high-impact medicines Structure Therapeutics Provides Comprehensive Study Neurocrine opening two Phase 1 trials in oral Parkinson’s therapies Bearing Fruit: Deep Apple Therapeutics Launches to Screen AI-Generated Virtual Libraries AbbVie to Acquire Cerevel Therapeutics in Transformative

  • Chemical Drug Matter : Rethinking the Molecules We Choose to Develop In Drug Discovery

    This approach reveals: Hidden target overlap New therapeutic hypotheses “Off-target” effects that may This reroutes discovery toward: Functionally selective ligands Better therapeutic windows More predictable What matters now is not the category , but the fit: Does the chemical matter support the therapeutic

  • Exciting GPCR Events for Next Year! + GPCR Weekly Rocket Launch ⦿ Oct 28 - Nov 3, 2024

    et al. for their fantastic review on Molecular and structural insights into the 5-HT2C receptor as a therapeutic IPO to $331m Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR- Targeted Antibody Therapeutics Using Generative AI Zombie Fungi Hijack Hosts’ Brains GPCR Therapeutics, Inc. has received Orphan Drug 20th World Congress of Basic and Clinical Pharmacology GPCR Jobs Scientist I Cell Biology - Tectonic Therapeutic proteins in obesity and diabetes mellitus Molecular and structural insights into the 5-HT2C receptor as a therapeutic

  • Sweet taste receptor agonists attenuate macrophage IL‐1β expression and eosinophilic inflammation...

    Eosinophilic inflammation is a hallmark of refractory chronic rhinosinusitis (CRS) and considered a major therapeutic (ECRS) via macrophage IL‐1β overproduction, thereby suggesting autophagy regulation as a potential therapeutic We sought to investigate the therapeutic potential of autophagy‐enhancing agent, trehalose, or related Methods We investigated the therapeutic effects of trehalose and saccharin on macrophage IL‐1β production

  • 📰 GPCR Weekly News, January 22 to 28, 2024

    Xavier Leroy on his appointment as CEO of GIO Therapeutics! Congratulations to Domain Therapeutics for being awarded the RHU SPRINT consortium grant. Endocrinology, and Taste The Role of Gut Microbiota and Associated Compounds in Cardiovascular Health and its Therapeutic Living Cells with Cucurbit[7]uril and Hemicyanine as a "Turn-On" Fluorescence Probe Industry News Domain Therapeutics Xavier Leroy appointed as CEO of GIO Therapeutics GPCR Events, Meetings, and Webinars NOW!

  • Adenosine receptor signalling in Alzheimer's disease

    Emerging evidence suggests adenosine G protein-coupled receptors (GPCRs) are promising therapeutic targets In this review, we provide an accessible summary of the literature on Alzheimer's disease and the therapeutic allosterism and the targeting of oligomers, which may increase drug discovery success and enhance the therapeutic

  • Adenosine receptor signalling in Alzheimer's disease

    Emerging evidence suggests adenosine G protein-coupled receptors (GPCRs) are promising therapeutic targets In this review, we provide an accessible summary of the literature on Alzheimer's disease and the therapeutic allosterism and the targeting of oligomers, which may increase drug discovery success and enhance the therapeutic

  • How a Failed Experiment Created a Powerful GPCR Imaging Tool

    not just the pancreas This tool helped clarify: Which neurons respond Which cell populations drive therapeutic metabolic therapy Guide how next-generation incretin drugs are designed Support cell-targeted conjugate therapeutic

  • Orthosteric vs. Allosteric Interactions: The Silent Decider of Safety and Success

    That choice determines whether you risk over- or under-dosing, miss safety windows, or miss therapeutic More nuanced control, fewer off-target liabilities, and novel therapeutic windows. Correctly distinguishing these mechanisms helps refine therapeutic index calculations, prioritize safer

  • Why Sokhom Pin Never Left GPCRs, Even When Everyone Else Did

    Advances in biased signaling, allosterism, and endosomal signaling have opened new therapeutic frontiers

  • 📰 GPCR Weekly News, May 8 to 14, 2023

    2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study Addex Therapeutics Research Council (ERC) Addex Reports Q1 2023 Financial Results And Provides Corporate Update Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights OMass Therapeutics presented at the BioEquity Conference British Patient Capital Invests £10m in next-generation drug development company OMass Therapeutics GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics

  • From Ox Liver to AI: How the History of Pharmacology Shapes Its Future

    👉 Join Terry’s Corner, your essential launchpad into the world of therapeutic science Unlock "The History

  • 📰 GPCR Weekly News, April 17 to 23, 2023

    GPCRs in Neuroscience G protein coupled receptors as targets for transformative neuropsychiatric therapeutics GPCRs in Oncology and Immunology CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment Inversago Pharma will present at BBHIC 2023 Orion Biotechnology attended the Swiss Biotech Day Addex Therapeutics GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics

  • Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies

    Few therapeutic agents have shown benefits when administered alone, but a few more have demonstrated clear improvement when administered in combination with other therapeutic molecules. In 2008 (and for the first time in the clinic), the therapeutic benefits of the β-adrenergic receptor

  • GPCR Happy Hour – Boston, Sept 2025

    delivers cutting-edge imaging and analysis that accelerates the discovery of new and life-changing therapeutics comprehensive approach enables Axxam to support clients worldwide in identifying and optimizing new therapeutic

  • GPCR Weekly Whirlwind: Top Receptor Highlights from Sep 30 - Oct 6, 2024!

    Receptor Bryan Roth  and Brian Krumm  for their excellent study on Molecular glues as potential GPCR therapeutics November 7th : Drug Disposition in Physiological Tissues as a Therapeutic Variable. December 5th : Unique Exploitable GPCR-Ligand Behaviors for Therapeutic Benefit. modulation of the prostaglandin EP4 receptor GPCR Binders, Drugs, and more Molecular glues as potential GPCR therapeutics

  • 📰 GPCR Weekly News, July 1 to 7, 2024

    September 5th to 26th, 2024 Overview: GPCRs have been and arguably still are the most prolific and fertile therapeutic trade-offs in whitefly G protein-coupled receptor kinases in hypertension: physiology, pathogenesis, and therapeutic proteins block the internalization of cognate GPCRs and disrupt downstream intracellular signaling Therapeutic acute and chronic relaxin-3 receptor (RXFP3) activation in the rat retrosplenial cortex Unveiling the therapeutic

  • Transformative GPCR Insights: Unleash New Horizons in Science | Sep 9 - 15, 2024

    Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic Industry News MBX aims for $136M IPO to take potential rival to Ascendis' Yorvipath into phase 3 Certa Therapeutics proteins for biology and health research Innovate UK announced the winners of its Transforming Cancer Therapeutics

  • 📰 GPCR Weekly News, October 2 to 8, 2023

    This week's highlight: Congrats to our partner GPCR Therapeutics, on their expansion into fibrosis with selectivity Industry News Sosei Heptares and Verily Nominate First G-protein-coupled receptor Target for Therapeutic Nearly $900K in NIH Funding to Discover Antibodies Against Difficult and Conserved Protein Targets GPCR Therapeutics

bottom of page